Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Kyverna Therapeutics, Inc. ( (KYTX) ) just unveiled an announcement.
On January 29, 2026, Kyverna Therapeutics announced that Chief Technology Officer Karen Walker would retire effective February 9, 2026, with the company emphasizing that her departure was not due to any disagreement over its operations, policies or practices and that she would continue in a consultative role to support the biologics license application for miv-cel in stiff person syndrome. On the same date, Kyverna’s compensation committee amended its 2024 Inducement Equity Incentive Plan to increase the pool of common shares available for inducement equity awards by 1 million to a total of 5 million shares, a move that expands the company’s capacity to use equity incentives to attract new talent without shareholder approval under Nasdaq rules. On February 3, 2026, Kyverna further strengthened its push toward commercial manufacturing of CAR T-cell therapies by appointing veteran manufacturing executive Mayo Pujols as Chief Technology Officer, effective February 9, 2026, and granting him a 300,000-share stock option as an inducement to join, signaling the company’s intent to bolster late-stage and commercial-scale technical operations as it advances miv-cel toward potential registration and launch in autoimmune indications.
The most recent analyst rating on (KYTX) stock is a Buy with a $10.50 price target. To see the full list of analyst forecasts on Kyverna Therapeutics, Inc. stock, see the KYTX Stock Forecast page.
Spark’s Take on KYTX Stock
According to Spark, TipRanks’ AI Analyst, KYTX is a Neutral.
The score is held back primarily by weak financial performance (no current revenue, widening losses, and accelerating cash burn). Offsetting this are constructive price trends and a strong slate of positive clinical and financing-related corporate events that improve the catalyst outlook and financial flexibility. Valuation contributes modestly given a negative P/E and no dividend yield.
To see Spark’s full report on KYTX stock, click here.
More about Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. Its lead product candidate, miv-cel (mivocabtagene autoleucel, KYV-101), is an autologous CD19-targeting CAR T-cell therapy aimed at B-cell-driven autoimmune disorders, underpinning a neuroimmunology franchise that includes a completed registrational trial in stiff person syndrome and an ongoing registrational trial in generalized myasthenia gravis, along with additional KYSA and investigator-initiated trials in indications such as multiple sclerosis and rheumatoid arthritis.
Average Trading Volume: 1,486,104
Technical Sentiment Signal: Strong Buy
Current Market Cap: $457.6M
Find detailed analytics on KYTX stock on TipRanks’ Stock Analysis page.